California State Teachers Retirement System Has $58.65 Million Position in Regeneron Pharmaceuticals, Inc. (REGN)
California State Teachers Retirement System trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 131,173 shares of the biopharmaceutical company’s stock after selling 13,349 shares during the period. California State Teachers Retirement System owned about 0.12% of Regeneron Pharmaceuticals worth $58,650,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. FMR LLC grew its stake in Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after acquiring an additional 416,192 shares in the last quarter. BlackRock Inc. grew its stake in Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock worth $3,039,305,000 after acquiring an additional 41,406 shares in the last quarter. Vanguard Group Inc. grew its stake in Regeneron Pharmaceuticals by 2.9% in the 2nd quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock worth $2,588,533,000 after acquiring an additional 148,962 shares in the last quarter. Harding Loevner LP grew its stake in Regeneron Pharmaceuticals by 589.2% in the 3rd quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock worth $286,619,000 after acquiring an additional 3,131,966 shares in the last quarter. Finally, Artisan Partners Limited Partnership grew its stake in Regeneron Pharmaceuticals by 1.5% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock worth $963,852,000 after acquiring an additional 29,252 shares in the last quarter. Institutional investors own 66.67% of the company’s stock.
REGN has been the topic of a number of research analyst reports. J P Morgan Chase & Co restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 31st. Barclays downgraded shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and dropped their target price for the stock from $450.00 to $395.00 in a research note on Friday, October 20th. Evercore ISI dropped their target price on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating on the stock in a research note on Thursday, November 16th. Guggenheim restated a “buy” rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $490.00 price target (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $465.22.
In related news, Director Michael S. Brown sold 1,500 shares of the stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total transaction of $712,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the sale, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. Corporate insiders own 10.80% of the company’s stock.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at $386.67 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $340.09 and a 52-week high of $543.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. The company has a market cap of $41,540.00, a P/E ratio of 33.01, a P/E/G ratio of 1.50 and a beta of 1.53.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. During the same quarter in the prior year, the company posted $3.13 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.0% compared to the same quarter last year. equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.dailypolitical.com/2017/12/14/california-state-teachers-retirement-system-has-58-65-million-position-in-regeneron-pharmaceuticals-inc-regn.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.